Ozempic (semaglutide) and Mounjaro (tirzepatide) are related medications approved for type 2 diabetes, not weight management
In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)," the substance sold as TB-500, on Category 2 of its interim 503A bulk drug substances list, meaning FDA identified significant safety concerns and would not permit licensed compounding pharmacies to use it
None of these are FDA-approved cognitive drugs, and the right consideration, if any, depends entirely on a clinical evaluation rather than a chart
Sobo Helps Patients Think Through Recovery Peptides Dr
398(10317):21602172., Pivotal Phase 2 monotherapy
basic mechanisms and clinical applications American Academy of Anti-Aging Medicine Thymosin beta 4 (Tb4) professional monograph (indications, dosage) Bachem Technical Note Peptide stability and handling guidelines International Journal of Clinical Pharmacy (2013) Evaluation of maximum beyond-use-date stability of peptide solutions CDC Vaccine administration: subcutaneous route (angle, site rotation guidance) WADA Prohibited List (2024) Growth factors and peptides prohibited in sport Arthroscopy (2025) Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review PubMed (2010) Randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers CDC (Subcut Injection PDF) Technique diagram and site guidance for subcutaneous injections NCBI Bookshelf Administration of parenteral medications: best practices Additional Research and Background These sources provide related context and are not presented as support for a specific statement above
